Jefferies not seeing significant impact to Merck, Bristol from draft guidance

TipRanks

Thu, May 15, 2025, 10:46 AM 1 min read

Jefferies expert Akash Tewari notes that caller Medicare Part B & D draught guidance has been released and that Merck (MRK) and Bristol Myers (BMY) are trading down owed to updated connection connected azygous root qualifying drugs. The updated connection connected azygous root qualifying fixed dose combo products successful the draught makes it look arsenic if subcutaneous Keytruda/Opdivo volition beryllium eligible for dialog successful 2028, but “We’re not definite this is true,” says the analyst, who is not seeing a important interaction to Merck and Bristol. The steadfast thinks subQ Keytruda/Opdivo whitethorn beryllium exempt from IRA dialog connected biosimilar entry, akin to HD Eylea, and believes changes whitethorn make an opening for Merck to settee with immoderate biosimilars earlier Keytruda’s ’28 nonaccomplishment of exclusivity and “therefore beryllium EXCLUDED from IRA negotiation.” Since subQ and IV Keytruda are present some “considered the aforesaid drug,” theoretically subQ Keytruda “may ne'er get IRA negotiated,” the expert added.

• Quickly and easy unpack a company's show with TipRanks' caller KPI Data for astute concern decisions

• Receive undervalued, marketplace resilient stocks consecutive to you inbox with TipRanks' Smart Value Newsletter

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected MRK:

Disclaimer & DisclosureReport an Issue

• UnitedHealth, Wayfair downgraded: Wall Street’s apical expert calls

• SCHD ETF News, 5/14/2025

• U.S. biotech companies statement relocating trials extracurricular U.S., Reuters reports

• Merck downgraded to Neutral from Buy astatine Citi

• Merck & Company: Navigating Medicare Drug Price Negotiation Challenges with Potential Upside